Axitinib Licensed by Pfizer

Catalog No.S1005

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Price Stock Quantity  
USD 64 In stock
USD 70 In stock
USD 120 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Axitinib Chemical Structure

Axitinib Chemical Structure
Molecular Weight: 386.47

Validation & Quality Control

4 customer reviews :

Quality Control & MSDS

Related Compound Libraries

VEGFR Inhibitors with Unique Features

Product Information

  • Compare VEGFR Inhibitors
    Compare VEGFR Products
  • Research Area
  • Axitinib Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Targets VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)

 View  More

IC50 0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM
In vitro Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
EoL-1-cellM{CxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTBwMECwNFUyOyEQvF2=MVfTRW5ITVJ?
NCI-H1703MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPnV3BKSzVyPUCuNFAxQTB{IN88US=>MkLGV2FPT0WU
KASUMI-1M1X4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGH3NWxKSzVyPUCuNFA3QDJizszNMlfNV2FPT0WU
CGTH-W-1MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlO2TWM2OD1yLkCwO|IzKM7:TR?=MX;TRW5ITVJ?
A204NHWye41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYTMcYc5UUN3ME2wMlAxQTl{IN88US=>M2LIZ3NCVkeHUh?=
HOP-62NVuxR5dOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIXWNmlKSzVyPUCuNVA5OzZizszNNH7Xd4hUSU6JRWK=
H-EMC-SSM1PwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTBwMUGwNFUh|ryPM3vPRXNCVkeHUh?=
KU812NGjNVnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;oT2lEPTB;MD6xOlU4PyEQvF2=Ml3ZV2FPT0WU
EM-2MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGLsWoJKSzVyPUCuNVY5OTZizszNNHXWUJdUSU6JRWK=
LAMA-84M{LGbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\YTWM2OD1yLkG3OlY2KM7:TR?=NYS0VGRsW0GQR1XS
JARNH3vfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGS3UZhKSzVyPUCuNlM6QDlizszNMXHTRW5ITVJ?
G-361NWP1NJBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLLfHBEUUN3ME2wMlMzOzJ3IN88US=>M3qybnNCVkeHUh?=
KG-1M1mzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{nJNGlEPTB;MD6zO|Y1OiEQvF2=NXK2W3JWW0GQR1XS
BV-173MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETofHhKSzVyPUCuN|k{OiEQvF2=M1fYZ3NCVkeHUh?=
K5MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmWzTWM2OD1yLkSyNVI4KM7:TR?=NWTWVFJ1W0GQR1XS
MEG-01M{njd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2f5O2lEPTB;MD60NlM3OSEQvF2=NF60SmtUSU6JRWK=
MFM-223MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXQVWJKSzVyPUCuOFQ4PzZizszNNHnHOXJUSU6JRWK=
BE-13MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYj2b3FbUUN3ME2wMlUyODB6IN88US=>MV;TRW5ITVJ?
NEC8NFXvR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFjETVBKSzVyPUCuO|IyOTNizszNNFuxbmhUSU6JRWK=
SW756MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3vhRmlEPTB;MD65PVg1PiEQvF2=MnPBV2FPT0WU
A2780MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2riSGlEPTB;MT6wNVE1PiEQvF2=MXrTRW5ITVJ?
NB14NHfoPG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2L1emlEPTB;MT6wNVgxOSEQvF2=NXXzWGJQW0GQR1XS
H4M1:0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEH2[lJKSzVyPUGuNFY1OjJizszNMmfwV2FPT0WU
SK-OV-3NF7Dfo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRTFwME[2N|Mh|ryPNYnFfGVpW0GQR1XS
AN3-CAM3v2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGHHWFJKSzVyPUGuNFg{QDlizszNM4fWcnNCVkeHUh?=
A427M12xNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLvTWM2OD1zLkGwN|gyKM7:TR?=MkfuV2FPT0WU
ES7MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjqRW1KSzVyPUGuNVE{OzRizszNM{P6PHNCVkeHUh?=
AGSM4PKS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI[2PYJKSzVyPUGuNVE{QTVizszNNEC3Om5USU6JRWK=
G-402NHu1fllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTLTWM2OD1zLkG0Olk1KM7:TR?=M1vQV3NCVkeHUh?=
ES5NH;NSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzETWM2OD1zLkG3NlQ5KM7:TR?=Ml3iV2FPT0WU
DELNFLTUWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTFwMkW0OVch|ryPNVP0OYF4W0GQR1XS
NB10M3fPRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGW1bG1KSzVyPUGuN|I2PTdizszNMlTDV2FPT0WU
NCI-H1581M{HoN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{LEZmlEPTB;MT6zPVA1OiEQvF2=MUDTRW5ITVJ?
D-566MGMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmTCTWM2OD1zLkSwOlg{KM7:TR?=NIjQflZUSU6JRWK=
LXF-289M2\UVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYH5dpp1UUN3ME2xMlQ{QTl4IN88US=>NV7zR29WW0GQR1XS
BT-549NIDIV3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTFwNU[5NFkh|ryPM{O3cXNCVkeHUh?=
NKM-1MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfXTWM2OD1zLk[wOVU3KM7:TR?=MmnZV2FPT0WU
SW780MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX\DNIxMUUN3ME2xMlY2OTV6IN88US=>NEW4TVZUSU6JRWK=
NCI-H292NUi2eI1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTFwNk[zPFMh|ryPMm[wV2FPT0WU
HMV-IIMonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXpZ4pKSzVyPUGuO|A1QDhizszNMoHJV2FPT0WU
ALL-PONXvZN41HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnnETWM2OD1zLkiwNFE2KM7:TR?=M3;iN3NCVkeHUh?=
UACC-257NH[1d2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2n2[2lEPTB;MT64NlE3OyEQvF2=NUXxUFFrW0GQR1XS
PA-1MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUL0ZnFDUUN3ME2xMlgzPzJ3IN88US=>NWXv[3pUW0GQR1XS
HD-MY-ZM1rzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrZdZVKSzVyPUGuPFYzQDFizszNNIXJdnVUSU6JRWK=
HSC-4MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnoTWM2OD1zLkmzPFM6KM7:TR?=M2\heHNCVkeHUh?=
GCTMoLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXQd2xKSzVyPUKuNFA6OTZizszNMnLzV2FPT0WU
RT-112MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{LPc2lEPTB;Mj6xN|QzPCEQvF2=NEXk[GxUSU6JRWK=
A172NILPc2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1zFc2lEPTB;Mj6xN|YxPiEQvF2=NGDKO4VUSU6JRWK=
HCE-TMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPCSJNKSzVyPUKuNlA2QThizszNNH\NUIVUSU6JRWK=
YH-13NHmz[GJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlSwTWM2OD1{LkKxOlcyKM7:TR?=MlXkV2FPT0WU
DK-MGMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGTncotKSzVyPUKuNlM5OzRizszNM{PocnNCVkeHUh?=
ACNMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTJwMkO4O|Uh|ryPMWTTRW5ITVJ?
VA-ES-BJM13aVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NInE[WlKSzVyPUKuNlQ6PTdizszNMoHwV2FPT0WU
L-363M1vwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkO1TWM2OD1{LkK4NFYyKM7:TR?=MWTTRW5ITVJ?
HuH-7NUWzN5lRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUf3SVNyUUN3ME2yMlQzOTZ3IN88US=>NV33RWlyW0GQR1XS
A4-FukM{HVZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmjjTWM2OD1{LkS3NVY5KM7:TR?=NFnQ[WdUSU6JRWK=
T-24MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3S2[2lEPTB;Mj60PFA{PyEQvF2=MVnTRW5ITVJ?
GOTOM4PRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlT1TWM2OD1{LkWzNFE{KM7:TR?=MlvFV2FPT0WU
MV-4-11Ml3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTJwNUmxOlkh|ryPMXnTRW5ITVJ?
DMS-114MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHvNPIJKSzVyPUKuOlY{PDVizszNMYrTRW5ITVJ?
MHH-NB-11NIW1eYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHvLVXZKSzVyPUKuO|AzQTlizszNNVTUeppKW0GQR1XS
CHP-212M{S2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFrUd4NKSzVyPUKuPFIxQTFizszNNUT5e3hFW0GQR1XS
DMS-273MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljhTWM2OD1{LkmwNlA4KM7:TR?=MUDTRW5ITVJ?
SF295MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NET1cmNKSzVyPUOuNFI2QTdizszNNFHNXItUSU6JRWK=
NCI-H1563NFO5cJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWr5PVk2UUN3ME2zMlE2ODB3IN88US=>MkDtV2FPT0WU
NCI-H446MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3z5ZWlEPTB;Mz6yNlgxPSEQvF2=MX3TRW5ITVJ?
HCC1806NG[0V4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmrDTWM2OD1|LkK3OlU4KM7:TR?=NU\KUppJW0GQR1XS
SF126MnrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\ubWlEPTB;Mz6zNFAyPyEQvF2=NV7EOFVRW0GQR1XS
SW982NY\RZpBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTNwM{O4O|Uh|ryPM1S1ZnNCVkeHUh?=
ES8NVLEbVdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYLyOpIzUUN3ME2zMlM1QTl7IN88US=>NIHRemtUSU6JRWK=
SCC-4M1\RcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjUZYNKSzVyPUOuOVA{QTZizszNMmTnV2FPT0WU
RPMI-8226MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTNwNkK2NVYh|ryPNXfr[G05W0GQR1XS
EW-11MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYrO[npRUUN3ME2zMlY{ODJ{IN88US=>MnrrV2FPT0WU
COR-L105MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXib4pKSzVyPUOuOlM{OzRizszNM3fzNHNCVkeHUh?=
ES1MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVvx[mw{UUN3ME2zMlg{ODl2IN88US=>NYjXWGFHW0GQR1XS
KMOE-2M{PUcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGTOfHBKSzVyPUOuPVE5ODhizszNNW\lcmR4W0GQR1XS
ABC-1NHn2WW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTNwOUO5NVEh|ryPM370U3NCVkeHUh?=
NCI-H526M3qyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlf2TWM2OD1|Lkm5NVI3KM7:TR?=M{jMdnNCVkeHUh?=
HCC1395MljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTNwOUm0PFQh|ryPNGP6UoNUSU6JRWK=
DU-145NYjpdItNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3nsRmlEPTB;ND6xNlgzPSEQvF2=MmWwV2FPT0WU
JEG-3MnTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIDJOJlKSzVyPUSuNVU6OTZizszNNGThXFVUSU6JRWK=
HCC1187MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XDdGlEPTB;ND6yNVU6PyEQvF2=MXnTRW5ITVJ?
LC-2-adMoe1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmLCTWM2OD12LkKyNVc4KM7:TR?=M2LHfHNCVkeHUh?=
ONS-76MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWHOdZVsUUN3ME20MlI1OTl{IN88US=>NVXoW2FUW0GQR1XS
CAL-27NE\rWHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml7DTWM2OD12LkK0N|Q1KM7:TR?=M4HxfHNCVkeHUh?=
8-MG-BAMoDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTRwMk[2OVgh|ryPMV3TRW5ITVJ?
HGC-27NGLQUIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWX4d5RIUUN3ME20MlI6PjZizszNNFnlTZBUSU6JRWK=
Hs-578-TNGjNWHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEj3U4JKSzVyPUSuN|E1PjhizszNM1;FSXNCVkeHUh?=
EW-1M{jQVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTRwNUOwNVQh|ryPNUfmSZN4W0GQR1XS
SW1573NGfv[G1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTRwNUWxOlMh|ryPMorCV2FPT0WU
SNU-423NHrq[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3XYN2lEPTB;ND62NFc6KM7:TR?=MmrqV2FPT0WU
HOSNETnZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTRwNkm3O{DPxE1?NYjocGY6W0GQR1XS
LB1047-RCCMmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYTrcVkxUUN3ME20MlgyPDF6IN88US=>MW\TRW5ITVJ?
ChaGo-K-1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml6wTWM2OD12Lki5NFQ5KM7:TR?=NVrMPY9sW0GQR1XS
A3-KAWMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M13uUmlEPTB;ND65O|M2OiEQvF2=M{PrNXNCVkeHUh?=
CAS-1MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHm0fYtKSzVyPUSuPVk6ODhizszNMV3TRW5ITVJ?
NBsusSRMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{jCc2lEPTB;NT6wN|UyPCEQvF2=NIPGelhUSU6JRWK=
KM12MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTVwMkm4Nlch|ryPM3PweHNCVkeHUh?=
NCI-H1155M3TYUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1T4VWlEPTB;NT6zPFE5PSEQvF2=M3\3dnNCVkeHUh?=
EFM-19NEDsbYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGD5NWJKSzVyPUWuOFE4OzdizszNNYmwOJdtW0GQR1XS
D-392MGM{LIe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\KTWM2OD13LkW3PFQ6KM7:TR?=MUfTRW5ITVJ?
JVM-3MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWX3RWhqUUN3ME21MlczOzJ3IN88US=>M2fub3NCVkeHUh?=
EW-16NW\wSYpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTVwN{W1PFMh|ryPNYH4epB6W0GQR1XS
KARPAS-45MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTVwOESzNlUh|ryPM4n1RnNCVkeHUh?=
NCI-H28NXPXV4RnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIrQWGFKSzVyPUWuPFc6OThizszNMlTCV2FPT0WU
COLO-829NX\5bnM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17BTmlEPTB;NT65NVUxPCEQvF2=NVmwW4lMW0GQR1XS
KM-H2NWXBeFB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEXq[YhKSzVyPUWuPVI{QTVizszNMVLTRW5ITVJ?
NCI-H82NUjRcoRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTVwOUK3O|Eh|ryPMUPTRW5ITVJ?
OAW-42NF[3eIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml60TWM2OD13Lkm4PFIyKM7:TR?=NVO5XI5UW0GQR1XS
A704M2XMcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1LJXmlEPTB;Nj6xNFU4PCEQvF2=NEnyN5FUSU6JRWK=
NCI-H1048NVfhVYY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjGc2JPUUN3ME22MlExPTl7IN88US=>M3;w[3NCVkeHUh?=
LOXIMVIMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTZwMUGyOFgh|ryPMVrTRW5ITVJ?
MKN45Mn7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYHsd|JEUUN3ME22MlI3ODF4IN88US=>M4D3TXNCVkeHUh?=
D-502MGNVTkN|ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1G4OGlEPTB;Nj6yPFg2PyEQvF2=NY\nfHBLW0GQR1XS
HUTU-80M4TnOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLjPI1lUUN3ME22MlQyPjh6IN88US=>NFG4XI9USU6JRWK=
S-117M4XkTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1vmfGlEPTB;Nj61NFI3PyEQvF2=M3q2NnNCVkeHUh?=
HCC1569M2PQfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfXZ49KSzVyPU[uOVM4OzdizszNMn7ZV2FPT0WU
J-RT3-T3-5NEjsfWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXXY[Fg2UUN3ME22MlU1PTd{IN88US=>MUXTRW5ITVJ?
OC-314MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnf2TWM2OD14LkmxNVU6KM7:TR?=MmCzV2FPT0WU
SNU-449NVPkdHp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlnRTWM2OD15LkCxNFczKM7:TR?=MV;TRW5ITVJ?
NCI-H720NXG3eowyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NETOcFZKSzVyPUeuNVk{PDVizszNNIL4TIJUSU6JRWK=
KP-N-YSMkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXqSXFKSzVyPUeuNlA4OiEQvF2=NXnEdYZ{W0GQR1XS
IGROV-1MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1XxeWlEPTB;Nz6zNlM5PiEQvF2=M4G0W3NCVkeHUh?=
SK-PN-DWNFvsVlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfoTWM2OD15LkS4NVUh|ryPMmjEV2FPT0WU
HCC1419M2TUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;CbHo1UUN3ME23MlU{KM7:TR?=NVL5bo1XW0GQR1XS
HAL-01Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4HST2lEPTB;Nz62NFY1PCEQvF2=MnywV2FPT0WU
HCC2998NXLuem9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUnvb41sUUN3ME23MlYxPzR|IN88US=>MYDTRW5ITVJ?
SK-N-FIMoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoH0TWM2OD15Lk[zNFM{KM7:TR?=MorsV2FPT0WU
GI-ME-NM{e5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlizTWM2OD15Lk[0PVM1KM7:TR?=NIn0W5NUSU6JRWK=
SW1088NWDGRoVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEX4ZoJKSzVyPUeuOlU5OjZizszNM3jTXXNCVkeHUh?=
IA-LMM3PVT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjhPVJKSzVyPUeuOlg3OTNizszNM{nFOnNCVkeHUh?=
SK-NEP-1NGLwbVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTdwNkm2NUDPxE1?M2CyUnNCVkeHUh?=
MDA-MB-415MmrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkPlTWM2OD15Lki5NVg3KM7:TR?=NYT5RoQ4W0GQR1XS
COLO-800MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXndmdKSzVyPUeuPVQ1QTJizszNMXfTRW5ITVJ?
NCI-H2228MnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHH3VJlKSzVyPUiuNVU4QDNizszNM4qxV3NCVkeHUh?=
D-423MGNVK0Xnc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYS1RYdLUUN3ME24MlIyPzJizszNMXnTRW5ITVJ?
TE-1NGCzVnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYTNXVB5UUN3ME24MlQ1OzF4IN88US=>MXTTRW5ITVJ?
NOS-1NETScYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRThwNUG1N|Qh|ryPMo\0V2FPT0WU
8505CNVvwdVZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRThwNkS4NlQh|ryPNXr3Vpl1W0GQR1XS
HEC-1MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4n2RWlEPTB;OD63PFQ{QSEQvF2=MXXTRW5ITVJ?
TE-11MkPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUX4NFlOUUN3ME24Mlk6PTVzIN88US=>NIHsVWdUSU6JRWK=
CTB-1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXmTWM2OD17LkCxOFM{KM7:TR?=NIrHXmtUSU6JRWK=
TGBC11TKBMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTlwMEKyOFEh|ryPMke4V2FPT0WU
NB17MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIDIblRKSzVyPUmuNVg5PyEQvF2=M3G3OnNCVkeHUh?=
BeckerNV32c2FNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmLpTWM2OD17LkSxPVQ1KM7:TR?=MUDTRW5ITVJ?
SN12CMmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{XWN2lEPTB;OT60OVI{PCEQvF2=MVfTRW5ITVJ?
COLO-320-HSRNWLkXmd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTlwNkCyN|ch|ryPMkWyV2FPT0WU
D-283MEDMn;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjvflFsUUN3ME25MlY{ODd{IN88US=>NFXRd41USU6JRWK=
D-263MGNV\LcWpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWrJR|UxRTlwOEOzPFQh|ryPNGfVcZRUSU6JRWK=
MEL-JUSONH\OeW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfQTWM2OD17LkmwNVI4KM7:TR?=MXLTRW5ITVJ?
T98GNGi1V2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4TaUmlEPTB;OT65NFIxOyEQvF2=MorMV2FPT0WU
HLEMlXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4HqemlEPTB;OT65NFkxQSEQvF2=Mki1V2FPT0WU
Ca9-22NHz5dpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2G2XWlEPTB;MUCuNFY3PSEQvF2=MoHxV2FPT0WU
OS-RC-2MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTFyLkGwOFUh|ryPM4XaZXNCVkeHUh?=
T47DNH7LTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkHYTWM2OD1zMD6xOVUh|ryPMWjTRW5ITVJ?
GI-1Mle4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jyUGlEPTB;MUCuN|U{OyEQvF2=MnjrV2FPT0WU
NUGC-3M4S5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXTzT4dZUUN3ME2xNE41PDB{IN88US=>MV;TRW5ITVJ?
MDA-MB-361MkXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEX3e|BKSzVyPUGwMlQ1OzJizszNMXrTRW5ITVJ?
SCC-15NEnmVZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITOc|RKSzVyPUGwMlQ4OThizszNMmrTV2FPT0WU
KS-1NEjzbYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XmVWlEPTB;MUCuOlMxOSEQvF2=NGTBflFUSU6JRWK=
CAL-12TNF:zSoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYDJR|UxRTFyLk[zOlEh|ryPM2LOSnNCVkeHUh?=
OVCAR-4NXvSS5dVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVGxV3I5UUN3ME2xNE44ODZ6IN88US=>M2fxW3NCVkeHUh?=
HuP-T4NU\LZZgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIrjUGZKSzVyPUGxMlA{OjhizszNMkfiV2FPT0WU
NCI-H358NED2O2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TyO2lEPTB;MUGuNlY2PyEQvF2=NIjtS25USU6JRWK=
HO-1-N-1MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml62TWM2OD1zMT6zN|k5KM7:TR?=NWnidYhIW0GQR1XS
NH-12NXW0RohyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;jO5lyUUN3ME2xNU42Ozd6IN88US=>NUfjOm9zW0GQR1XS
MOLT-4MmixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1L4WGlEPTB;MUGuOVk5PSEQvF2=MlXMV2FPT0WU
K-562MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTFzLkeyOFgh|ryPMXrTRW5ITVJ?
ES6MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEPuZYRKSzVyPUGxMlg2QDFizszNM{TTVXNCVkeHUh?=
RO82-W-1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEK4T4VKSzVyPUGxMlkxPjRizszNM1jqcXNCVkeHUh?=
Ramos-2G6-4C10NYnZU3ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3rkOWlEPTB;MUGuPVMzKM7:TR?=M{nidnNCVkeHUh?=
23132-87NWrQ[GJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnzXTWM2OD1zMj6wPFIyKM7:TR?=MkTCV2FPT0WU
A549NH\DfHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkXBTWM2OD1zMj6zNlg2KM7:TR?=NUDmTGExW0GQR1XS
NCI-H23NVH2RoUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTF{LkWwNlYh|ryPMl\SV2FPT0WU
H9NYPCWI54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mlr4TWM2OD1zMj61OVc4KM7:TR?=MUXTRW5ITVJ?
LB771-HNCMmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjOTWM2OD1zMj63OlUh|ryPNXTlSFVyW0GQR1XS
QIMR-WILNEjndWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnnBTWM2OD1zMj64NlU5KM7:TR?=NEfHWZpUSU6JRWK=
HSC-3MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHX0fHFKSzVyPUGyMlkzPzZizszNM17qN3NCVkeHUh?=
PFSK-1NUPmW|BUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTF{Lkm1NFch|ryPNFTkWVNUSU6JRWK=
ETK-1NGnKcYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTF|LkC3O|kh|ryPNHPQNGFUSU6JRWK=
SW1710NULLbFJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX3VNWtZUUN3ME2xN{4{PjRzIN88US=>NYLrcm1CW0GQR1XS
COLO-684MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTF|LkS1OFEh|ryPMYrTRW5ITVJ?
RPMI-7951NVP4O2lRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlLTTWM2OD1zMz61NVM3KM7:TR?=MX;TRW5ITVJ?
A101DMkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTF|LkWzOFkh|ryPNVHSNoRZW0GQR1XS
KE-37MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTF|LkW4PFch|ryPNFXwUFZUSU6JRWK=
SiHaNH;Q[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M37Ob2lEPTB;MUOuPFM1PiEQvF2=NGjzNGtUSU6JRWK=
NCI-H226M{\CZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWPIWoh2UUN3ME2xN{45QDB6IN88US=>NXzW[pd{W0GQR1XS
DBNVPpXVF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7iTWM2OD1zMz65PVI5KM7:TR?=NGXF[JpUSU6JRWK=
HT-1197NF\EVlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUf2coZRUUN3ME2xOE4xQDB7IN88US=>NYfUXHlOW0GQR1XS
SBC-5NH63SWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFjod3pKSzVyPUG0MlE{PjJizszNMlW1V2FPT0WU
VMRC-RCZMojmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXt[nlKSzVyPUG0MlU4PzRizszNM13renNCVkeHUh?=
697MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTF2Lk[yO{DPxE1?M1\Ob3NCVkeHUh?=
OMC-1NUf5cZBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm[2TWM2OD1zND63PFg5KM7:TR?=NYXyc3RJW0GQR1XS
SKG-IIIaM36zXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTF2LkiwNFEh|ryPNGLpV2pUSU6JRWK=
DOKM1ztSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVrIVo41UUN3ME2xOE46QTN|IN88US=>NGLvSYtUSU6JRWK=
NCI-H2029NGPqOXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nJ[GlEPTB;MUWuN|YxOiEQvF2=MknyV2FPT0WU
NCI-H2009M2DRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;1dHVPUUN3ME2xOU42ODl3IN88US=>NVPYSHd1W0GQR1XS
LK-2NGnwNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUnHXop[UUN3ME2xOU43PDR7IN88US=>NHrse2RUSU6JRWK=
NCI-H661M17YWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1zj[GlEPTB;MUWuPVA4PSEQvF2=M4r6fnNCVkeHUh?=
GT3TKBMYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnWTWM2OD1zNj6wOlc3KM7:TR?=MXXTRW5ITVJ?
GP5dM2G1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NET4[JZKSzVyPUG2MlM1OiEQvF2=Ml3TV2FPT0WU
SK-MEL-2NU\BfWt6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1X5Z2lEPTB;MU[uOFQ5PSEQvF2=NFzzboxUSU6JRWK=
SK-UT-1M3LQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnz4TWM2OD1zNj61OlUh|ryPMknMV2FPT0WU
NB7NWrEemFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWO3OoZJUUN3ME2xOk43QTdzIN88US=>MoHjV2FPT0WU
NCI-H460MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEnlXm1KSzVyPUG2Mlc{OjZizszNMl3vV2FPT0WU
8305CM{[yT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1f4b2lEPTB;MU[uO|g4PyEQvF2=MlPuV2FPT0WU
CaR-1Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3X1RmlEPTB;MU[uPFEyOSEQvF2=M2XhZ3NCVkeHUh?=
D-247MGNEfkOpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVWyVml{UUN3ME2xOk45PjJ3IN88US=>MmfxV2FPT0WU
LoVoNYjyZnVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHiTWM2OD1zNj65OFg5KM7:TR?=MnjaV2FPT0WU
NCI-H2405NG\0fnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTF5LkG5NFgh|ryPNVjBS4p3W0GQR1XS
AU565NX;PcJVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1zq[WlEPTB;MUeuNlI2KM7:TR?=M1:zeXNCVkeHUh?=
OCI-AML2NU\meop5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWq2SoFUUUN3ME2xO{42OzF5IN88US=>NWP5Z2prW0GQR1XS
22RV1NHnleG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTF5LkW4PFQh|ryPNYLCXG1IW0GQR1XS
HT-144NXH4cmdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTF5Lk[1PVgh|ryPNYfDN5lFW0GQR1XS
HuO9M4XWXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkHiTWM2OD1zNz63NFMyKM7:TR?=MnH5V2FPT0WU
DaoyNGX4Oo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGDEWWNKSzVyPUG3MlcyQDRizszNMXTTRW5ITVJ?
SJRH30MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3HpbmlEPTB;MUeuPFQ5QSEQvF2=M2G1dnNCVkeHUh?=
CHL-1MmTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFfTbGJKSzVyPUG3MlkzPDlizszNM2PDR3NCVkeHUh?=
J82NHvMWFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF3NOpdKSzVyPUG3Mlk3OzVizszNMVvTRW5ITVJ?
COR-L23NIfhfXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYD4OJB5UUN3ME2xPE4xODFzIN88US=>NXPQU5JWW0GQR1XS
SNU-C2BMl;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MljHTWM2OD1zOD6yNlc3KM7:TR?=NUnrenpjW0GQR1XS
NCI-H1770MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYHvUGIyUUN3ME2xPE41PjF3IN88US=>NH21dXFUSU6JRWK=
MHH-PREB-1MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHLaXVdKSzVyPUG4MlU3QTdizszNNGnVXHFUSU6JRWK=
ES3NGGzb5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH7RVlRKSzVyPUG4MlU5QDNizszNNH;jdFVUSU6JRWK=
MDA-MB-231NVviVVRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjTV|BxUUN3ME2xPE43PTB{IN88US=>M1\qbHNCVkeHUh?=
MN-60NIDWelhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzxTWM2OD1zOT6wOVkzKM7:TR?=MkHoV2FPT0WU
EPLC-272HM3y0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmHlTWM2OD1zOT6zO|A5KM7:TR?=NHPERopUSU6JRWK=
SW948M2PtSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTF7LkO5N|Qh|ryPNUf6TnpKW0GQR1XS
MOLT-13M4f0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfRPJpEUUN3ME2xPU41PTR4IN88US=>MWrTRW5ITVJ?
HL-60Mn\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn;sTWM2OD1{MD6yNVQyKM7:TR?=MVXTRW5ITVJ?
CP50-MEL-BMnHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmHpTWM2OD1{MD60O|Q5KM7:TR?=NH;rXlJUSU6JRWK=
NTERA-S-cl-D1NVnZNVV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHxSnBTUUN3ME2yNE41QTd6IN88US=>MVTTRW5ITVJ?
KINGS-1MmS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3fEU2lEPTB;MkCuO|k3PyEQvF2=MknSV2FPT0WU
DOHH-2NX\hZYNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M37xZ2lEPTB;MkCuPVA3KM7:TR?=Mn21V2FPT0WU
BB65-RCCNFrOZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3e0VGlEPTB;MkCuPVI5PSEQvF2=MYPTRW5ITVJ?
NB12NVLpcFB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1jFOGlEPTB;MkGuNFM6PCEQvF2=NFH0elZUSU6JRWK=
KY821MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEHtdG9KSzVyPUKxMlU5OiEQvF2=MVHTRW5ITVJ?
PSN1NYPVTlUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHX5ZVJKSzVyPUKxMlY1PTNizszNMUPTRW5ITVJ?
EGI-1M1OwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnIcXd1UUN3ME2yNU44PDV2IN88US=>NF3XN3dUSU6JRWK=
CTV-1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoTlTWM2OD1{Mj6zNFMyKM7:TR?=NEfDc2ZUSU6JRWK=
TI-73M{Txcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTJ{LkO0PVgh|ryPNET5fVJUSU6JRWK=
LCLC-103HNIrWeGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYjaOZQ3UUN3ME2yNk41PzV{IN88US=>MkTRV2FPT0WU
D-542MGMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3HTWM2OD1{Mj61OVU5KM7:TR?=MmPsV2FPT0WU
ATN-1M3nhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFr4V|lKSzVyPUKyMlY1OzlizszNNGOyRYFUSU6JRWK=
SK-MEL-1M{HOdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLRTWM2OD1{Mj64N|Y5KM7:TR?=M4ruSHNCVkeHUh?=
HDLM-2NHrKcY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUXVfW1rUUN3ME2yN{4yPDd6IN88US=>MWnTRW5ITVJ?
UM-UC-3NHK2T29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\wWlhKUUN3ME2yN{4yQTR2IN88US=>NF7CcIRUSU6JRWK=
NCI-H1573M4r5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7rTWM2OD1{Mz60OlgyKM7:TR?=M4K0[HNCVkeHUh?=
NCI-H520M1LERWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTJ|LkS5OFgh|ryPM1PDTHNCVkeHUh?=
ESS-1NIrOT2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWfMdJgzUUN3ME2yN{45ODV7IN88US=>NHvkWHdUSU6JRWK=
COR-L88MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfZTWM2OD1{Mz65OFc2KM7:TR?=Mm\kV2FPT0WU
TGBC24TKBMlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTJ2LkCzNVIh|ryPM4O2UnNCVkeHUh?=
HCC1937NEPHTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\1TWM2OD1{ND6xJO69VQ>?NFL2T4VUSU6JRWK=
RS4-11MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRTJ2LkG0NkDPxE1?NYn3dZFZW0GQR1XS
HCC38M2jYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPuS5ZYUUN3ME2yOE4zOzl2IN88US=>NHiwdolUSU6JRWK=
RPMI-2650MmnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYrLb2luUUN3ME2yOE43OTZ{IN88US=>M3ryT3NCVkeHUh?=
P12-ICHIKAWAMknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFjTcYZKSzVyPUK0MlYzPThizszNNFPi[pZUSU6JRWK=
YAPCM4TuSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4fzcGlEPTB;MkSuPFIyPCEQvF2=NFPSWHpUSU6JRWK=
NB13MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn[1TWM2OD1{NT6yOlEyKM7:TR?=NH\wNGFUSU6JRWK=
SK-N-ASMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MorwTWM2OD1{NT64OVg1KM7:TR?=MWHTRW5ITVJ?
SK-N-DZNYrVZW46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;uc4JSUUN3ME2yOk4xPDlizszNMV;TRW5ITVJ?
LS-411NNULzUFFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH:xSGxKSzVyPUK2MlIxOzhizszNM2rDTXNCVkeHUh?=
NCI-H810NI[yRW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTJ4LkOxNVIh|ryPM4f4dXNCVkeHUh?=
NCI-SNU-1NGry[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\XenJKSzVyPUK2MlU1PTRizszNM1rxbnNCVkeHUh?=
HHMkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFrxO3JKSzVyPUK2MlU2OjlizszNM1LqTXNCVkeHUh?=
U-2-OSMmPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\KTWM2OD1{Nj63N|gzKM7:TR?=MmHxV2FPT0WU
SF539NELTfpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH3TVYlKSzVyPUK2MlgxOThizszNNYPafGtUW0GQR1XS
NCI-H2052M4nSfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTJ5LkC4OkDPxE1?NYDpb2luW0GQR1XS
A673NVK5fG9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTJ5LkKxNFIh|ryPMYXTRW5ITVJ?
WM-115NYnmSVZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPYb5JKSzVyPUK3Mlc4PjdizszNMX3TRW5ITVJ?
SW48M3P6cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITFepJKSzVyPUK3MlgxODVizszNMoKxV2FPT0WU
NOMO-1MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTJ5Lki1N|Ih|ryPM1HpPHNCVkeHUh?=
PC-3NGP5NYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkPrTWM2OD1{Nz64PVQyKM7:TR?=NEDLTIpUSU6JRWK=
UMC-11M3nwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlGyTWM2OD1{Nz65N|Q{KM7:TR?=M4iwVXNCVkeHUh?=
U-118-MGNULkW3dtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4HGR2lEPTB;MkiuNFEzOyEQvF2=NXHZTpRTW0GQR1XS
NCI-H2452MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXjTWM2OD1{OD6wPFIzKM7:TR?=NX7w[GJjW0GQR1XS
CAMA-1NF76d4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPvTWM2OD1{OD64OVY1KM7:TR?=M2nHVHNCVkeHUh?=
MC-IXCMn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXX5d5VYUUN3ME2yPU4zOzZ4IN88US=>M{HJNHNCVkeHUh?=
ES4M1nL[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTJ7LkOxO|Ih|ryPM2jVOXNCVkeHUh?=
BHT-101NICyb|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;HOGlEPTB;MkmuN|IyKM7:TR?=NXHIOIpTW0GQR1XS
KP-4MnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTJ7LkWxOkDPxE1?MXrTRW5ITVJ?
CAL-54MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnw[IN[UUN3ME2yPU42PDR3IN88US=>NVfETmJnW0GQR1XS
5637NILkW2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2SyemlEPTB;MkmuOlQzOSEQvF2=M3jRXHNCVkeHUh?=
MOLT-16MoTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLCPJpKSzVyPUK5MlczPjlizszNMYLTRW5ITVJ?
Ca-SkiM2\NN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXnSXZKSzVyPUK5Mlk1PiEQvF2=MkXQV2FPT0WU
AsPC-1M2nXfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjyTWM2OD1|MD6wNlEzKM7:TR?=MoruV2FPT0WU
MSTO-211HM3HnUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTNyLkG1JO69VQ>?NYrVN|lnW0GQR1XS
L-428M1rHSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3O3UGlEPTB;M{CuOFA2KM7:TR?=M{X5NXNCVkeHUh?=
SW1463NYPzdWw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVrEeJFCUUN3ME2zNE42Ozh|IN88US=>NXm2T2F3W0GQR1XS
NCI-H1648NIHvb5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmrzTWM2OD1|MD61OVc1KM7:TR?=MXrTRW5ITVJ?
CAKI-1NH\CVlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LpdGlEPTB;M{CuO|cxOiEQvF2=MlvDV2FPT0WU
YKG-1Mm\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmT3TWM2OD1|MT6wNlY{KM7:TR?=M4fRVHNCVkeHUh?=
A2058NHjRXI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTNzLkGxOlQh|ryPMX3TRW5ITVJ?
A375M2nQVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{L5fmlEPTB;M{GuNVY6PiEQvF2=Moe5V2FPT0WU
SNB75NGLje2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{S4PWlEPTB;M{GuNlQ{PSEQvF2=MojUV2FPT0WU
SK-HEP-1NYDQRodmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTNzLkSyO|Eh|ryPM1nhUHNCVkeHUh?=
ME-180NIXYd|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVLkS2xxUUN3ME2zNU43PTR{IN88US=>M2jsZnNCVkeHUh?=
NCI-H209NGXmb5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTSVYZKSzVyPUOxMlgzPDdizszNM1vZbXNCVkeHUh?=
HC-1NXq4NFcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTN{LkG0OFYh|ryPNUDaVY5nW0GQR1XS
LB373-MEL-DNWnFdYl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4P3OWlEPTB;M{KuNVk4OSEQvF2=MnLQV2FPT0WU
SNU-387NEjublFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWn2S|ZEUUN3ME2zNk4{OTlzIN88US=>MkfZV2FPT0WU
C32NILHToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHv1O3JKSzVyPUOyMlM{PTNizszNM2LYWHNCVkeHUh?=
EW-13NHL3WIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;mV2FKSzVyPUOyMlk1ODhizszNMkXwV2FPT0WU
BFTC-905MkXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3XZWmlEPTB;M{OuOVE{PiEQvF2=NGDBdpZUSU6JRWK=
NCI-H1299M{nmT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTN|LkW2NlEh|ryPM13ye3NCVkeHUh?=
LU-135M13mSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1PoeGlEPTB;M{OuPFAyKM7:TR?=NE\mbVFUSU6JRWK=
NCI-H2122MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHrrcJRKSzVyPUOzMlk6PjZizszNMXvTRW5ITVJ?
SK-LMS-1NYHvfJpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGGzVVBKSzVyPUO0MlQyODdizszNNF3GRnpUSU6JRWK=
LNCaP-Clone-FGCNV63T24xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkDrTWM2OD1|ND64OVE2KM7:TR?=MoTFV2FPT0WU
NCI-H1092MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVPBe3YyUUN3ME2zOU4zPzR5IN88US=>M2Pje3NCVkeHUh?=
MS-1MlLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2K2OGlEPTB;M{WuN|A{QCEQvF2=NXXIc41{W0GQR1XS
KYSE-510NGrQUXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFHuRmtKSzVyPUO1MlUxPDJizszNNITzV2FUSU6JRWK=
NCI-H1793MnLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTN3Lk[1OFUh|ryPM1HYcnNCVkeHUh?=
MIA-PaCa-2NVzocWNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4L5bWlEPTB;M{[uNFQ6PiEQvF2=MV7TRW5ITVJ?
EW-22M4\kXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVTQXXJLUUN3ME2zOk41ODd{IN88US=>MoC5V2FPT0WU
IGR-1NGHxclBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVTKclZUUUN3ME2zOk45OTh2IN88US=>M1e1UXNCVkeHUh?=
HT-1080NYDTeFRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHHoXI5KSzVyPUO3MlEzPSEQvF2=M3;yUXNCVkeHUh?=
M14NEH4NFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUC1O4tVUUN3ME2zO{4yPjR{IN88US=>M2T6OHNCVkeHUh?=
786-0NUHXUI1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX23XJBJUUN3ME2zO{4zPzl2IN88US=>NIXXSpZUSU6JRWK=
MZ2-MELMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRTN5LkS1NFEh|ryPM1TUUnNCVkeHUh?=
NCI-H510ANEPtR2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVTJR|UxRTN5Lkm0NVIh|ryPMoHRV2FPT0WU
LAN-6MlOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGn0cWNKSzVyPUO3Mlk2QDJizszNMkHWV2FPT0WU
SW620MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2LIVGlEPTB;M{iuOFk4PCEQvF2=M{nEenNCVkeHUh?=
LB2241-RCCM3X2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LCW2lEPTB;M{muPFIxPSEQvF2=MUXTRW5ITVJ?
Detroit562MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX61RoNFUUN3ME20NE4yOjZ6IN88US=>MneyV2FPT0WU
HNM4PMc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmHMTWM2OD12MD6xO|gzKM7:TR?=MkHVV2FPT0WU
HCT-15MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTRyLkW5NFch|ryPMm\hV2FPT0WU
C2BBe1MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\WO|JKSzVyPUSwMlkyPTdizszNM4H6RnNCVkeHUh?=
A498M2fEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHG3VXhKSzVyPUSxMlMxOTVizszNM4TYdXNCVkeHUh?=
SK-MEL-24NHrveZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mlm0TWM2OD12MT60O|I2KM7:TR?=NUDiRo1{W0GQR1XS
OVCAR-5NUjQUIlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1zsR2lEPTB;NEGuO|c3PyEQvF2=MXjTRW5ITVJ?
NCI-H1792NIH1cYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1yweWlEPTB;NEGuPVgzOSEQvF2=NGTGdY5USU6JRWK=
KOSC-2MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTR{LkK2PVkh|ryPM{fFNXNCVkeHUh?=
Mo-TM4XNcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7rW2xRUUN3ME20Nk45QTV6IN88US=>M2HxV3NCVkeHUh?=
CFPAC-1NFru[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRTR|LkS5OFQh|ryPMnjzV2FPT0WU
CAL-51MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3PVW9KSzVyPUSzMlU3ODVizszNMWTTRW5ITVJ?
RH-18M4D4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M13pU2lEPTB;NEOuPFA2KM7:TR?=Ml3wV2FPT0WU
EC-GI-10MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HWSGlEPTB;NEOuPFM1PyEQvF2=NH7COnJUSU6JRWK=
HSC-2NVrPSFlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnriTWM2OD12ND6wNFkh|ryPMXzTRW5ITVJ?
ML-2M3Xzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITYOmxKSzVyPUS1MlI3OjFizszNNXfWPHAzW0GQR1XS
KNS-81-FDNYDHR3ZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MljGTWM2OD12NT63N|Y2KM7:TR?=NYWyPWF3W0GQR1XS
NB6NEnQdHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{DvfmlEPTB;NE[uNVEyKM7:TR?=NV7I[VA{W0GQR1XS
MCF7NH3jUm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTR4LkW1N|Mh|ryPMnroV2FPT0WU
P30-OHKMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTR4LkixNVch|ryPMVnTRW5ITVJ?
BPH-1MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvob4ppUUN3ME20Ok46QDB3IN88US=>MnfqV2FPT0WU
U251NV3nfWFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWHwdlNEUUN3ME20Ok46QTRizszNMoO2V2FPT0WU
MKN1NWry[IRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUXjPVdlUUN3ME20O{42OTN5IN88US=>NGTnOFBUSU6JRWK=
A431M1rJfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2rKemlEPTB;NEeuPFM{QCEQvF2=NXH0d4l7W0GQR1XS
C8166NHrLdYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVr3XXJTUUN3ME20PU4zODN7IN88US=>NF7vRlZUSU6JRWK=
HELMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3vp[GlEPTB;NEmuOFA3PCEQvF2=NIfkeY1USU6JRWK=
RMG-INInIXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYjMXZBxUUN3ME20PU41PDR2IN88US=>NXznXmZtW0GQR1XS
CAL-72M1SyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYnzNIVIUUN3ME20PU43ODd3IN88US=>NGPsfFRUSU6JRWK=
SW962M2DzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{TjUGlEPTB;NEmuPVM{OiEQvF2=NV;3VlZvW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).

Protocol(Only for Reference)

Kinase Assay:

[1]

Cellular receptor kinase phosphorylation assay Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.

Cell Assay:

[2]

Cell lines HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
Concentrations 1 nM - 10 μM
Incubation Time 72 hours
Method

Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.

Animal Study:

[3]

Animal Models BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
Formulation 0.5% carboxymethylcellulose (CMC)
Dosages 10, 30 or 100 mg/kg
Administration Oral daily

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Hu-Lowe DD, et al. Clin Cancer Res, 2008, 14(22), 7272-7283.

[2] Rossler, J. et al., Int J Cancer, 2011, 128(11), 2748-2758.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02156895 Not yet recruiting Advanced Renal Cell Carcinoma Pfizer December 2016 --
NCT02782403 Not yet recruiting Leukemia M.D. Anderson Cancer Center|Pfizer August 2016 Phase 1|Phase 2
NCT02762513 Not yet recruiting Squamous Cell Carcinoma of the Head and Neck University of Michigan Cancer Center May 2016 Phase 2
NCT02684006 Recruiting Renal Cell Cancer Pfizer March 2016 Phase 3
NCT02636725 Recruiting Alveolar Soft Part Sarcoma|Soft Tissue Sarcomas Breelyn Wilky|Merck Sharp & Dohme Corp.|Pfizer|University  ...more Breelyn Wilky|Merck Sharp & Dohme Corp.|Pfizer|University of Miami March 2016 Phase 2

view more

Chemical Information

Download Axitinib SDF
Molecular Weight (MW) 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms AG 013736
Solubility (25°C) * In vitro DMSO 35 mg/mL warming (90.56 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 0.5% CMC 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-benzamide

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related VEGFR Products

  • SU5402

    SU5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC50 of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGF-Rβ, respectively.

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • R428 (BGB324)

    R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).

  • Regorafenib (BAY 73-4506)

    Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.

  • Cabozantinib (XL184, BMS-907351)

    Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively.

  • Nintedanib (BIBF 1120)

    Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM in cell-free assays. Phase 3.

  • Vandetanib (ZD6474)

    Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay.

  • Lenvatinib (E7080)

    Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β in cell-free assays. Phase 3.

  • Pazopanib

    Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

  • Pazopanib HCl (GW786034 HCl)

    Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

    Features:A multi-kinase inhibitor.

Recently Viewed Items

Tags: buy Axitinib | Axitinib ic50 | Axitinib price | Axitinib cost | Axitinib solubility dmso | Axitinib purchase | Axitinib manufacturer | Axitinib research buy | Axitinib order | Axitinib mouse | Axitinib chemical structure | Axitinib mw | Axitinib molecular weight | Axitinib datasheet | Axitinib supplier | Axitinib in vitro | Axitinib cell line | Axitinib concentration | Axitinib nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us